论文部分内容阅读
本文对老年人（≥65岁）和对照（＜65岁）AMI用尿激酶进行静脉溶栓治疗。结果发现：老年AMI典型胸痛发生率和溶栓后胸病完全缓解率及加速性室性自主律发生率均低于对照组。∑ST↓％、Rindex及CPK峰值前移同样适于作为老年AMI溶栓疗法冠脉再通的非创伤性金指标。但应注意部分老年AMI者因有肺气肿导致ECG低电压对判断ST段升降程度的影响及老年AMI溶栓后CPK峰值前移相对迟延这两个特点。老年溶栓出血发生率并不比对照组高，再通率与对照组相近。说明年龄绝不是一个独立影响溶栓疗法的因素，老年AMI施行静脉溶栓同样可以获得良好效果。
In this article, intravenous thrombolytic therapy with urokinase in the elderly (≥65 years) and control (<65 years) AMIs was performed. The results showed that: the incidence of AMI typical chest pain in elderly patients with thoracic thrombosis and thrombolytic complete remission rate and accelerated ventricular autonomy were lower than the control group. ΣST ↓%, Rindex and CPK peak forward also suitable as a noninvasive gold index of coronary recanalization in elderly AMI thrombolytic therapy. However, it should be noted that some elderly patients with AMI due to emphysema led ECG low voltage to determine the degree of ST-segment elevation and elderly patients with AMI after thrombolysis CPK peak forward relative delay of these two characteristics. Elderly thrombolytic bleeding rate was not higher than the control group, the pass rate and the control group similar. That age is by no means an independent factor affecting thrombolytic therapy, elderly intravenous thrombolytic therapy AMI can also get good results.